LIFECORE BIOMEDICAL, INC. \DE\ (LFCR): Entry into a Material Definitive Agreement
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lifecore Biomedical to be Acquired by Webster Equity Partners • Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium • Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in
How this was made
The 30-second read
Why it matters
The disclosed cash premium and CVR structure provide immediate valuation guidance, likely moving the stock toward the $6.28 offer price.
Market read
Primary M&A disclosure with a sizable cash premium; traders can act on the price gap and CVR upside.
What to watch
Potential regulatory hurdles and the go‑shop period could introduce deal risk, affecting the stock price before closing.
Background
The filing is an SEC Form 8‑K announcing Lifecore Biomedical's agreement to be acquired by private equity firm Webster Equity Partners.
Ticker impact
Lifecore Biomedical announced a definitive agreement to be acquired by Webster Equity Partners for $6.28 cash per share, a 49.5% premium.
likely upward pressure as the market prices in the cash offer, then pressure downwards after the deal closes and the stock delists.
Deal terms are disclosed for the first time, providing a clear valuation floor for shareholders.
Market effects
Consolidation in the CDMO biotech sector may prompt valuation reassessments for peers.
Limited to US biotech and Nasdaq listings; no broader regional effect.
Modest, as the deal size is mid‑cap and sector‑specific.
Counterpoint
If the CVR milestones are not met, total consideration could fall short of the headline $9.67 per share, limiting upside.
Key entities
- companyLifecore Biomedical, Inc.
Target of the acquisition, Nasdaq‑listed biotech CDMO.
- private_equity_firmWebster Equity Partners
Acquirer offering cash and CVRs.
